ENYO Pharma’s approach to discovery research has identified 40 largely unexplored novel human targets. Precursors that have been developed to modulate those target’s effects are active against Influenza virus. One small molecule starting point has been selected for lead optimisation. This chemical series modulates a small family of host proteins known to regulate mitochondrial metabolism and mitochondrial stress responses controlling autophagy and apoptosis. The family of proteins targeted by the EYP002 lead series is validated in therapeutic areas other than infectious disease and reorientation of the therapeutic application is thus being examined. The drug candidate is orally bioavailable and is expected to be IND ready by the end of 2018.